Regeneron Pharma Earnings, Revenue Beat in Q3

Investing.com – Regeneron Pharma (NASDAQ:) reported third quarter that beat analysts’ expectations on Tuesday and revenue that topped forecasts.

The firm reported earnings per share of $6.67 on revenue of $2.05B. Analysts polled by Investing.com expected EPS of $6.41 on revenue of $1.99B. That compared to EPS of $5.87 on revenue of $1.66B in the same period a year earlier. The company had reported EPS of $6.02 on revenue of $1.93B in the previous quarter.

Regeneron Pharma follows other major Healthcare sector earnings this month

On October 15, J&J reported third quarter EPS of $2.12 on revenue of $20.73B, compared to forecasts of EPS of $2.01 on revenue of $20.08B.

Merck&Co earnings beat analysts’ expectations on October 29, with third quarter EPS of $1.51 on revenue of $12.4B. Investing.com analysts expected EPS of $1.24 on revenue of $11.64B

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.